Formulation of hydrophobic peptides for skin delivery via coated microneedles

Abstract Microneedles (MNs) have been investigated as a minimally‐invasive delivery technology for a range of active pharmaceutical ingredients (APIs). Various formulations and methods for coating the surface of MNs with therapeutics have been proposed and exemplified, predominantly for hydrophilic drugs and particulates. The development of effective MN delivery formulations for hydrophobic drugs is more challenging with dosing restrictions and the use of organic solvents impacting on both the bioactivity and the kinetics of drug release. In this study we propose a novel formulation that is suitable for MN coating of hydrophobic auto‐antigen peptides currently being investigated for antigen specific immunotherapy (ASI) of type 1 diabetes. The formulation, comprising three co‐solvents (water, 2‐methyl‐2‐butanol and acetic acid) and polyvinylalcohol 2000 (PVA2000) can dissolve both hydrophilic and hydrophobic peptide auto‐antigens at relatively high, and clinically relevant, concentrations (25 mg/ml or 12.5 mg/ml). The drug:excipient ratio is restricted to 10:1 w/w to maximise dose whilst ensuring that the dry‐coated payload does not significantly impact on MN skin penetration performance. The coating formulation and process does not adversely affect the biological activity of the peptide. The delivery efficiency of the coated peptide into skin is influenced by a number of parameters. Electropolishing the metal MN surface increases delivery efficiency from 2.0 ± 1.0% to 59.9 ± 6.7%. An increased mass of peptide formulation per needle, from 0.37 &mgr;g to 2 &mgr;g peptide dose, resulted in a thicker coating and a 20% reduction in the efficiency of skin delivery. Other important performance parameters for coated MNs include the role of excipients in assisting dissolution from the MNs, the intrinsic hydrophobicity of the peptide and the species of skin model used in laboratory studies. This study therefore both exemplifies the potential of a novel formulation for coating hydrophobic and hydrophilic peptides onto MN devices and provides new insight into the factors that influence delivery efficiency from coated MNs. Importantly, the results provide guidance for identifying critical attributes of the formulation, coating process and delivery device, that confer reproducible and effective delivery from coated MNs, and thus contribute to the requirements of the regulators appraising these devices. Graphical abstract Figure. No Caption available.

[1]  M. Prausnitz,et al.  Stability Kinetics of Influenza Vaccine Coated onto Microneedles During Drying and Storage , 2010, Pharmaceutical Research.

[2]  Mark R Prausnitz,et al.  Coated microneedles for transdermal delivery. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[3]  Mahmoud Ameri,et al.  Transdermal delivery of desmopressin using a coated microneedle array patch system. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[4]  Ying Zhang,et al.  Development of Lidocaine-Coated Microneedle Product for Rapid, Safe, and Prolonged Local Analgesic Action , 2011, Pharmaceutical Research.

[5]  Miss A.O. Penney (b) , 1974, The New Yale Book of Quotations.

[6]  Christopher H Contag,et al.  Gene silencing following siRNA delivery to skin via coated steel microneedles: In vitro and in vivo proof-of-concept. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[7]  M. Peakman,et al.  Antigen-Specific Immunotherapy for Type 1 Diabetes: Maximizing the Potential , 2010, Diabetes.

[8]  C. Cho,et al.  Effect of microneedle on the pharmacokinetics of ketoprofen from its transdermal formulations , 2009, Drug delivery.

[9]  Mark R Prausnitz,et al.  Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[10]  F. Wong,et al.  Proinsulin peptide immunotherapy in type 1 diabetes: report of a first‐in‐man Phase I safety study , 2009, Clinical and experimental immunology.

[11]  M. Prausnitz,et al.  Delivery of salmon calcitonin using a microneedle patch. , 2012, International journal of pharmaceutics.

[12]  D. Lamprou,et al.  Inkjet printing of insulin microneedles for transdermal delivery , 2015, Drug Delivery and Translational Research.

[13]  Ryan F. Donnelly,et al.  A proposed model membrane and test method for microneedle insertion studies , 2014, International journal of pharmaceutics.

[14]  M Kietzmann,et al.  The mouse epidermis as a model in skin pharmacology: influence of age and sex on epidermal metabolic reactions and their circadian rhythms , 1990, Laboratory animals.

[15]  Yeu-Chun Kim,et al.  Formulation of Microneedles Coated with Influenza Virus-like Particle Vaccine , 2010, AAPS PharmSciTech.

[16]  M. Prausnitz,et al.  Microneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunity. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[17]  Jung-Hwan Park,et al.  Microneedles for drug and vaccine delivery. , 2012, Advanced drug delivery reviews.

[18]  R. Warner,et al.  Electron probe analysis of human skin: determination of the water concentration profile. , 1988, The Journal of investigative dermatology.

[19]  R. V. Kulkarni,et al.  Comparison of skin permeability of drugs in mice and human cadaver skin. , 2000, Indian journal of experimental biology.

[20]  D. Wraith,et al.  Antigen-specific immunotherapy of autoimmune and allergic diseases , 2010, Current opinion in immunology.

[21]  Zijing Li,et al.  Microneedles for transdermal delivery of insulin , 2015 .

[22]  Smita S. Pimple,et al.  FORMULATION AND EVALUATION OF COATED MICRONEEDLES FOR THE TREATMENT OF HAIRLOSS , 2014 .

[23]  Mark R. Prausnitz,et al.  Coating Formulations for Microneedles , 2007, Pharmaceutical Research.

[24]  M. Ameri,et al.  Human Growth Hormone Delivery with a Microneedle Transdermal System: Preclinical Formulation, Stability, Delivery and PK of Therapeutically Relevant Doses , 2014, Pharmaceutics.

[25]  H. Wulf,et al.  Epidermal thickness at different body sites: relationship to age, gender, pigmentation, blood content, skin type and smoking habits. , 2003, Acta dermato-venereologica.

[26]  James C Birchall,et al.  Microneedle delivery of plasmid DNA to living human skin: Formulation coating, skin insertion and gene expression. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[27]  M. Longaker,et al.  Surgical Approaches to Create Murine Models of Human Wound Healing , 2010, Journal of biomedicine & biotechnology.

[28]  Clemencia Pinilla,et al.  Identification of MHC Class II-Restricted Peptide Ligands, Including a Glutamic Acid Decarboxylase 65 Sequence, that Stimulate Diabetogenic T Cells from Transgenic BDC2.5 Nonobese Diabetic Mice1 , 2001, The Journal of Immunology.

[29]  S. C. Fan,et al.  Parathyroid Hormone PTH(1-34) Formulation that Enables Uniform Coating on a Novel Transdermal Microprojection Delivery System , 2010, Pharmaceutical Research.

[30]  Mark R Prausnitz,et al.  Intrastromal delivery of bevacizumab using microneedles to treat corneal neovascularization. , 2014, Investigative ophthalmology & visual science.

[31]  M. Prausnitz,et al.  Measles vaccination using a microneedle patch. , 2013, Vaccine.

[32]  A. Laurent,et al.  Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines. , 2007, Vaccine.

[33]  L. Wen,et al.  Microneedle delivery of autoantigen for immunotherapy in type 1 diabetes. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[34]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[35]  Harvey N. Mayrovitz,et al.  Assessing Free and Bound Water in Skin at 300 MHz Using Tissue Dielectric Constant Measurements with the MoistureMeterD , 2015 .

[36]  B. W. Barry,et al.  Limitations of hairless mouse skin as a model for in vitro permeation studies through human skin: hydration damage. , 1988, The Journal of investigative dermatology.

[37]  M. Prausnitz,et al.  Pocketed microneedles for rapid delivery of a liquid-state botulinum toxin A formulation into human skin. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[38]  Cwj Cees Oomens,et al.  Monitoring the penetration process of single microneedles with varying tip diameters. , 2014, Journal of the mechanical behavior of biomedical materials.